JUNO THERAPEUTICS INC's ticker is JUNO and the CUSIP is 48205A109. A total of 176 filers reported holding JUNO THERAPEUTICS INC in Q3 2016. The put-call ratio across all filers is 0.85 and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $70,000 | +12.9% | 1,515 | +10.3% | 0.00% | – |
| Q3 2017 | $62,000 | +34.8% | 1,373 | -12.4% | 0.00% | – |
| Q2 2017 | $46,000 | +31.4% | 1,568 | 0.0% | 0.00% | – |
| Q1 2017 | $35,000 | +20.7% | 1,568 | +0.6% | 0.00% | – |
| Q4 2016 | $29,000 | -50.0% | 1,558 | -18.0% | 0.00% | – |
| Q3 2016 | $58,000 | +81.2% | 1,900 | +137.5% | 0.00% | – |
| Q2 2016 | $32,000 | +33.3% | 800 | +33.3% | 0.00% | – |
| Q1 2016 | $24,000 | -46.7% | 600 | -40.0% | 0.00% | – |
| Q4 2015 | $45,000 | +40.6% | 1,000 | +23.6% | 0.00% | – |
| Q3 2015 | $32,000 | -87.5% | 809 | -83.1% | 0.00% | – |
| Q2 2015 | $256,000 | +433.3% | 4,800 | +500.0% | 0.00% | – |
| Q1 2015 | $48,000 | -56.0% | 800 | -61.9% | 0.00% | – |
| Q4 2014 | $109,000 | – | 2,100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 25,948,799 | $1,132,937,000 | 100.00% |
| Biomark Capital Management Co. LLC | 1,602,562 | $70,465,000 | 85.76% |
| Omega Fund Management, LLC | 1,229,512 | $54,062,000 | 30.09% |
| Clarius Group, LLC | 218,942 | $9,626,000 | 2.93% |
| BB BIOTECH AG | 1,305,000 | $57,381,000 | 1.62% |
| Casdin Capital, LLC | 17,500 | $769,000 | 0.68% |
| Rock Springs Capital Management LP | 197,001 | $8,662,000 | 0.66% |
| BENNETT LAWRENCE MANAGEMENT L L C/NY | 38,850 | $1,708,000 | 0.55% |
| ArrowMark Colorado Holdings LLC | 383,749 | $16,873,000 | 0.46% |
| SUFFOLK CAPITAL MANAGEMENT LLC | 68,848 | $3,027,000 | 0.38% |